HD-OPM Archive
Topics › LDL, ApoB & lipid panel

HDL-raising trials all failed: torcetrapib, dalcetrapib, evacetrapib and others

Louis Nervegna · Jul 28, 2025 · ♥ 5 reactions · 1 comments · original Facebook post
LDL, ApoB & lipid panelPCSK9, ezetimibe & newer drugs
↻ This is a repost. The main version (highest ranked) is HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal · Mar 11, 2024.
AI summary & key facts

Louis argues HDL/ApoA-1 is not a causal target. Three CETP inhibitor trials raised HDL or ApoA-I without cutting events, and fibrate, niacin and CSL112 trials also failed.

(no text — see the shared post below)

Research cited

Does HDL (ApoA-1) by itself play a major causal role in heart disease?

The answer from randomized controlled trials in humans is likely NO.

ApoA-1 is the main protein component of HDL in blood. Many studies have shown an association between lower levels of ApoA-1 (HDL) and higher risk of heart disease. The question is whether or not this association is actually causal?

Three major clinical trials testing drugs designed to raise HDL and apolipoprotein A-I (ApoA-I) levels in an attempt to reduce cardiovascular disease failed:

  1. ILLUMINATE Trial (torcetrapib)

Torcetrapib raised ApoA-I and HDL cholesterol levels substantially.

However, the trial was terminated early due to increased risk of cardiovascular events and mortality in the treatment group.

  1. dal-OUTCOMES Trial (dalcetrapib)

Dalcetrapib modestly raised ApoA-I and HDL-C levels by 30%.

But it did not reduce the risk of cardiovascular death, heart attack, or stroke compared to placebo.

  1. ACCELERATE Trial (evacetrapib)

Evacetrapib raised ApoA-I levels by over 100%. However, it did not significantly reduce major adverse cardiovascular events compared to placebo.

The trial was terminated early.

Other major trials also failed:

It’s not just the three CETP inhibitors mentioned above that have failed. Large trials that raised HDL and ApoA-1 by adding fibrates or niacin to standard of care failed.

Large trials of direct ApoA-1 therapies have also failed, e.g. CSL112. The recent failure of CSL112 in phase 3 was probably the nail in the coffin for ApoA-1 as directly causal. They literally gave the patients native ApoA-1 isolated from human plasma (CSL112) and it still failed.

↪ CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause

The same result occurs in Mendelian randomization studies. Genes that predispose people to higher HDL or ApoA-1 (without increasing insulin sensitivity) do not lower lifetime risk.

Summary:

Interventions to raise ApoA-1 and HDL have repeatedly failed to improve clinical outcomes in high-risk patient populations. The same result occurs in Mendelian randomization studies. This likely refutes the hypothesis that simply increasing circulating ApoA-I or HDL levels is sufficient by itself for cardiovascular risk reduction.

A possible explanation for the inverse association of ApoA-1 with heart disease is that ApoA-1 is an indirect marker (or proxy) for insulin sensitivity— and it is actually insulin sensitivity that is causal, as opposed to ApoA-1 itself. Higher levels of ApoA-1 likely reflect better insulin sensitivity, and thus lower risk for heart disease. Interventions that raise ApoA-1 or HDL without improving insulin sensitivity (like the drugs used in the clinical trials discussed above) are unlikely to lower risk for heart disease.

#hdlHD #tghdlratioHD #insulinresistanceHD #apoa1HD #cetpinhibitorHD #csl112HD #fibratesHD #niacinHD #vitaminb3HD

← newer: Low HDL is mostly a sign of insulin resistance; losing visceolder: HDL is a poor intervention target: every large HDL-raising t →